Verona Pharma plc (VRNA)
After hours:
- Globe Newswire
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-83
- GlobeNewswire
Andrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team. Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry. He brings a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercializat
- Insider Monkey
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript February 29, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. VRNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to Verona Pharma’s Fourth Quarter […]
